Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.33 USD | +1.65% | +4.11% | -0.99% |
13/05 | Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test | MT |
13/05 | Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.99% | 983.45Cr | |
+26.37% | 4.82TCr | |
-1.01% | 4.17TCr | |
+46.00% | 4.1TCr | |
-5.31% | 2.88TCr | |
+9.34% | 2.56TCr | |
-21.69% | 1.9TCr | |
+6.23% | 1.29TCr | |
+26.99% | 1.2TCr | |
-3.38% | 1.18TCr |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- BofA Securities Adjusts Price Target on Qiagen to $52 From $44, Maintains Buy Rating